← All trials
NCT06710080
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Jun 30, 2027
- First posted
- Nov 29, 2024
- Last posted
- Nov 29, 2024
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OttawaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.